FDA approves Tylenol with Naproxen as the first non-prescription fixed-dose acetaminophen and naproxen sodium combination

The approval provides adults and children aged 12 years and older with a single over-the-counter combination option that delivers both rapid and prolonged pain relief without requiring separate analgesic products.

The US Food and Drug Administration (FDA) has approved Tylenol with Naproxen (acetaminophen/naproxen sodium) for the temporary relief of pain, making it the first non-prescription fixed-dose combination of acetaminophen and naproxen sodium available in the United States.

The approval offers an additional over-the-counter pain management option for patients aged 12 years and older while providing a single-tablet formulation that combines two established non-opioid analgesics.

Field	Content
Alert Type	Drug Approval
Drug Name	Tylenol with Naproxen
Indication	Temporary relief of pain in adults and children aged 12 years and older.
Therapy Area(s)	Pain Management
Geography	US (FDA)
What Happened	On 24 July 2026, the FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets) for over-the-counter temporary pain relief in adults and children aged 12 years and older. The approval establishes the product as the first non-prescription fixed-dose combination of acetaminophen and naproxen sodium, providing up to 12 hours of pain relief in a single tablet formulation.
Why It Matters	The approval introduces a new over-the-counter treatment option that combines two well-established non-opioid analgesics in a fixed-dose product, potentially simplifying pain management for patients who would otherwise use separate acetaminophen and naproxen products. It expands the range of non-prescription analgesic options but does not alter existing safety precautions associated with acetaminophen- or NSAID-containing medicines.
Supporting Context	While other over-the-counter products combine acetaminophen with a non-steroidal anti-inflammatory drug, this is the first to combine acetaminophen specifically with naproxen sodium. FDA-approved labelling includes standard warnings for both acetaminophen- and NSAID-containing products, including liver toxicity and pregnancy-related precautions.
Key Takeaway	FDA approval adds the first fixed-dose acetaminophen and naproxen sodium combination to the US over-the-counter pain relief market, expanding non-prescription treatment choices for eligible patients.
What to Watch	Monitor commercial availability following the FDA approval and how the product is incorporated into over-the-counter pain management recommendations and consumer use.
Primary Source	https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour
Relevant Date	24 July 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com